Nuclear Medicine Market Size to be USD 19.47 Billion by 2028

Pune, India, January 18, 2023 (GLOBE NEWSWIRE) — Global

nuclear medicine market

The size was valued at US$5.04 billion in 2020 and US$5.57 billion in 2021. The market is expected to reach USD 19.47 by 2028, at a CAGR of 19.6% during the forecast period. The market growth is mainly due to the increasing incidence of chronic diseases. Additionally, technological advancements that allow radiopharmaceuticals to be used to analyze and treat cancerous tumors will help the market grow.

Fortune Business Insights™ Share this information in the report titled “Nuclear Medicine Market Forecast, 2023-2028.”

industrial development

Bracco Diagnostics Inc. has announced a collaboration with CardioNavix, LLC to enhance patient access to cardiac PET imaging. This new program, the Bracco Mobile Isotope Service, will enable more patient care sites to offer cardiac PET imaging.

Request a sample copy of the report:

Report scope and segmentation

driving factor

Technological advances in nuclear imaging modalities boosting the market

One of the fundamental aspects of the growth of the nuclear medicine market is the growing awareness of the potential impact of primary and timely diagnosis and positive agitation in long-term disability management and treatment. The development of nuclear imaging techniques, especially PET/PET-CT, has helped expand the application of this modality beyond oncology to cardiology, neurology, and the identification of infectious diseases.

important point

• Market players focusing on various strategies, such as new product launches, are expected to increase revenue over the next year.

• Development of new therapeutic products for treatment of various medical conditions stimulating market growth.

• North America is expected to generate USD 2.57 billion in 2020 and continue to dominate the market during the forecast period.

• Increasing prevalence of various cancers and other chronic diseases is expected to boost the growth of the North American market during the forecast period.

View full report details:

segmentation

Based on type, the market is segmented into diagnostic and therapeutic radiopharmaceuticals. The diagnostic radiopharmaceutical segment is estimated to hold a dominant share of the global market in 2020.

In terms of application, the market is segmented into neurology, cardiology, oncology, and others.

By end-user, the market is segmented into hospitals and clinics, diagnostic centers, and others.

Geographically, the market is branched into North America, Europe, Asia Pacific, and the rest of the world.

Regional Insight

North America Leads, Supported by Increased Use of Therapeutic Radiopharmaceuticals

North America is expected to generate a revenue of US$2.57 billion in 2020 and maintain its dominance during the forecast period. Rapid adoption of pooled operational nuclear imaging technology with increasing utilization of technically sound and proficient therapeutic radiopharmaceuticals across the region is expected to boost the market growth.

Europe is estimated to hold the second highest nuclear medicine market share due to advanced radiopharmaceutical adoption and current product launches by prominent players.

Asia Pacific is projected to expand at a significant CAGR during the forecast period.

competitive environment

Partnerships initiated by key players to drive market growth

Dominant players of the market continuously endorse resourceful strategies to enhance their brand value and drive the growth of the global market for their products while facing unimaginable obstacles. One such effective strategy is to acquire a competitive firm and enhance the interests of both firms involved.

Access full report –

nuclear medicine

market:

https://www.fortunebusinessinsights.com/checkout-page/101812

List of major players covered in the report

• Lantheus Medical Imaging, Inc. (USA)

• Cardinal Health (United States)

• Norgine BV (Netherlands)

• Nordion (Canada) Inc. (Canada)

• Bayer AG (Germany)

• Curium (France)

• Advanced Accelerator Applications (Novartis AG) (France)

• Bracco Diagnostic Inc. (USA)

• Jubilant Pharmova Limited (India)

• GE Healthcare (General Electric Company) (U.S.)

Main points of the table of contents:

• prologue

  • Market range

  • market segmentation

  • research method

  • definitions and assumptions

• executive summary

• market dynamics

  • market driver

  • market constraints

  • market opportunity

  • Market trend

• key insight

  • Installed Base of PET/PET-CT Scanners – Select Countries, 2015 and 2019

  • Gamma Camera Installed Base – Selected Countries, 2019

  • PET/PET-CT treatment volumes – selected countries, 2019

  • Redemption scenarios – for major countries

  • New product launch

  • major industry developments

  • Pipeline analysis

  • Market Impact of COVID-19

• Global Nuclear Medicine Market Analysis, Insights and Forecasts, 2017-2028

  • Main Findings/Summary

  • Market Analysis, Insights & Forecasts – By Type

    • diagnose

      • PET Radiopharmaceutical

        • FDG-PET/18F

        • 68Ga

        • 68Cu

        • 11C

        • others

      • SPECT radiopharmaceuticals

        • Technetium-99m

        • Iodine-123

        • Xenon-133

        • Thallium-201

        • others

    • Therapeutics

  • Market Analysis, Insights & Forecasts – By Application

    • neurology

    • cardiology

    • oncology

    • others

  • Market Analysis, Insights & Forecasts – By End User

    • hospitals and clinics

    • diagnostic center

    • others

  • Market Analysis, Insights & Forecasts – By Region

    • North America

    • Europe

    • Asia Pacific

    • rest of the world

• North America Nuclear Medicine Market Analysis, Insights and Forecasts, 2017-2028

  • Main Findings/Summary

  • Market Analysis, Insights & Forecasts – By Type

    • diagnose

      • PET Radiopharmaceutical

        • FDG-PET/18F

        • 68Ga

        • 68Cu

        • 11C

        • others

      • SPECT radiopharmaceuticals

        • Technetium-99m

        • Iodine-123

        • Xenon-133

        • Thallium-201

        • others

    • Therapeutics

  • Market Analysis, Insights & Forecasts – By Application

    • neurology

    • cardiology

    • Oncology

    • others

  • Market Analysis, Insights & Forecasts – By End User

    • hospitals and clinics

    • diagnostic center

    • others

  • Market Analysis, Insights & Forecasts – By Country

• European Nuclear Medicine Market Analysis, Insights and Forecasts, 2017-2028

  • Main Findings/Summary

  • Market Analysis, Insights & Forecasts – By Type

    • diagnose

      • PET Radiopharmaceutical

        • FDG-PET/18F

        • 68Ga

        • 68Cu

        • 11C

        • others

      • SPECT radiopharmaceuticals

        • Technetium-99m

        • Iodine-123

        • Xenon-133

        • Thallium-201

        • others

    • Therapeutics

TOC Continuing…

Questions? Ask the Experts:

https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/nuclear-medicine-radiopharmaceuticals-market-101812

Related Links:

Radiation dose management market

Scale, Share, Revenue Forecast, Opportunity

Radiation therapy market

Overview, industry share, forecast

Digital radiography market

Scale, Share, Opportunity, Analysis

about us:

Fortune Business Insights™ provides professional enterprise analytics and accurate data to help organizations of all sizes make timely decisions. We tailor innovative solutions for our clients to help them address their unique business challenges. Our goal is to provide clients with holistic market information and provide a detailed overview of the markets in which they operate. Our report contains a unique mix of concrete insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market research interspersed with relevant data.

inquiry:

Fortune Business Insights™ Pvt.

USA: +1 424 253 0390

UK: +44 2071 939123

Asia Pacific: +91 744 740 1245

Email:

sales@fortunebusinessinsights.com